EP3653622A4 - AMINOPYRIMIDINE COMPOUND, COMPOSITION COMPRISING SAME AND USE THEREOF - Google Patents

AMINOPYRIMIDINE COMPOUND, COMPOSITION COMPRISING SAME AND USE THEREOF Download PDF

Info

Publication number: EP3653622A4
Authority: EP; European Patent Office
Prior art keywords: composition; same; aminopyrimidine compound; aminopyrimidine; compound
Prior art date: 2017-08-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP18849590.7A

Other languages

German (de)

French (fr)

Other versions

EP3653622A1 (en

EP3653622B1 (en

Inventor

Yihan Wang

Huanyin LI

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shenzhen Targetrx Inc

Original Assignee

Shenzhen Targetrx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-30

Filing date

2018-08-21

Publication date

2020-06-17

2018-08-21 Application filed by Shenzhen Targetrx Inc filed Critical Shenzhen Targetrx Inc

2020-05-20 Publication of EP3653622A1 publication Critical patent/EP3653622A1/en

2020-06-17 Publication of EP3653622A4 publication Critical patent/EP3653622A4/en

2022-12-28 Application granted granted Critical

2022-12-28 Publication of EP3653622B1 publication Critical patent/EP3653622B1/en

Status Active legal-status Critical Current

2038-08-21 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP18849590.7A 2017-08-30 2018-08-21 Aminopyrimidine compound and composition comprising same and use thereof Active EP3653622B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201710765745		2017-08-30
PCT/CN2018/101471 WO2019042187A1 (en)	2017-08-30	2018-08-21	Aminopyrimidine compound and composition comprising same and use thereof

Publications (3)

Publication Number	Publication Date
EP3653622A1 EP3653622A1 (en)	2020-05-20
EP3653622A4 true EP3653622A4 (en)	2020-06-17
EP3653622B1 EP3653622B1 (en)	2022-12-28

Family

ID=64472943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP18849590.7A Active EP3653622B1 (en)	2017-08-30	2018-08-21	Aminopyrimidine compound and composition comprising same and use thereof

Country Status (5)

Country	Link
US (1)	US11267810B2 (en)
EP (1)	EP3653622B1 (en)
JP (1)	JP6985764B2 (en)
CN (2)	CN108947974B (en)
WO (1)	WO2019042187A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111349084B (en) *	2018-12-21	2022-11-25	深圳市塔吉瑞生物医药有限公司	Aminopyrimidines useful for inhibiting protein kinase activity
CN111747950B (en)	2019-03-29	2024-01-23	深圳福沃药业有限公司	Pyrimidine derivatives for the treatment of cancer
CN116462663A (en) *	2023-06-20	2023-07-21	北京科翔中升医药科技有限公司	Pyrimidine bi-deuterated pyrazole compound, pharmaceutical composition and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995026325A2 (en) *	1994-03-25	1995-10-05	Isotechnika Inc.	Enhancement of the efficacy of drugs by deuteration
WO2016060443A2 (en) *	2014-10-13	2016-04-21	Yuhan Corporation	Compounds and compositions for modulating egfr mutant kinase activities

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
SI3205650T1 (en) *	2014-10-11	2021-10-29	Shanghai Hansoh Biomedical Co Ltd	Egfr inhibitor, and preparation and application thereof
CN104788427B (en) *	2015-02-05	2017-05-31	上海泓博智源医药股份有限公司	3 (2 pyrimdinyl-amino) phenylacryloyl amine compounds and its application
JP2019501222A (en) *	2016-01-07	2019-01-17	シーエスファーマテックリミテッド	Selective inhibitors of clinically important variants of EGFR tyrosine kinase
CN109467585A (en)	2016-03-11	2019-03-15	深圳市塔吉瑞生物医药有限公司	For preventing or treating the disease mediated cholane acid compound of FXR-

2018
- 2018-08-21 WO PCT/CN2018/101471 patent/WO2019042187A1/en not_active Ceased
- 2018-08-21 CN CN201810952626.0A patent/CN108947974B/en active Active
- 2018-08-21 EP EP18849590.7A patent/EP3653622B1/en active Active
- 2018-08-21 CN CN202010353107.XA patent/CN111518082B/en active Active
- 2018-08-21 US US16/641,715 patent/US11267810B2/en active Active
- 2018-08-21 JP JP2020512676A patent/JP6985764B2/en active Active

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995026325A2 (en) *	1994-03-25	1995-10-05	Isotechnika Inc.	Enhancement of the efficacy of drugs by deuteration
WO2016060443A2 (en) *	2014-10-13	2016-04-21	Yuhan Corporation	Compounds and compositions for modulating egfr mutant kinase activities

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CONCERT PHARMACEUTICALS INC: "Precision Deuterium Chemistry Backgrounder", INTERNET CITATION, January 2009 (2009-01-01), pages 1 - 6, XP009169265, Retrieved from the Internet <URL:http://www.concertpharma.com/about/documents/ConcertProductPlatformBackgrounder.pdf> [retrieved on 20130430] *
DUMONT ET AL: "Prospects in the use of deuterated molecules as therapeutic agents", REVUE IRE, INSTITUT NATIONAL DES RADIOELEMENTS, BELGIUM, vol. 6, no. 4, January 1982 (1982-01-01), pages 2 - 10, XP009125461, ISSN: 0770-1160 *
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, January 1985 (1985-01-01), pages 1 - 40, XP009086953, ISSN: 0065-2490 *
O'DRISCOLL: "Heavyweight drugs", CHEMISTRY & INDUSTRY, SOCIETY OF CHEMICAL INDUSTRY. LONDON, GB, 9 March 2009 (2009-03-09), pages 24 - 26, XP002636700, ISSN: 0009-3068 *
See also references of WO2019042187A1 *
YARNELL: "Heavy-Hydrogen Drugs Turn Heads, Again", INTERNET CITATION, 22 June 2009 (2009-06-22), pages 36 - 39, XP002546075, Retrieved from the Internet <URL:http://pubs.acs.org/cen/science/87/8725sci1.html> [retrieved on 20090916] *

Also Published As

Publication number	Publication date
EP3653622A1 (en)	2020-05-20
JP2020531565A (en)	2020-11-05
JP6985764B2 (en)	2021-12-22
EP3653622B1 (en)	2022-12-28
CN108947974A (en)	2018-12-07
CN108947974B (en)	2020-06-05
US11267810B2 (en)	2022-03-08
CN111518082A (en)	2020-08-11
WO2019042187A1 (en)	2019-03-07
US20200207751A1 (en)	2020-07-02
CN111518082B (en)	2021-09-17

Publication	Publication Date	Title
IL274297A (en)	2020-06-30	Pyrazolo-piperidine substituted indole-2-carboxamides, compositions comprising same and uses thereof
IL272089B1 (en)	2023-05-01	Compounds, preparations and methods
IL268588A (en)	2019-09-26	Anti-gprc5d antibodies, compositions comprising same and uses thereof
EP3385255A4 (en)	2019-08-14	FUNGICIDAL COMPOUND, FUNGICIDAL COMPOSITION, PREPARATION THEREOF, AND USE THEREOF
IL263373A (en)	2018-12-31	Genetically modified vaccinia virus, compositions containing same and uses thereof
DK3676297T3 (en)	2023-08-14	COMPOUNDS, COMPOSITIONS AND METHODS
DK3580561T3 (en)	2023-12-18	HLA-BASED METHODS, COMPOSITIONS AND USES THEREOF
MA47440A (en)	2019-12-11	SULPHONYLURIDES, RELATED COMPOUNDS, AND THEIR USE
EP3521384A4 (en)	2019-11-27	IONIC COMPOUND, COATING COMPOSITION AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME
PL3407888T3 (en)	2021-08-30	Pyridopyrroloquinoxaline compounds, their compositions and applications
DK3347472T3 (en)	2022-11-21	Compositions containing cyp76ad1-clade polypeptides and use thereof.
EP3466943A4 (en)	2019-07-03	DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3434676A4 (en)	2019-09-11	SUBSTITUTED CDK PYRROLOPYRIMIDINE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND USE THEREOF
EP3428171A4 (en)	2019-02-13	COMPOUND AND COLOR CONVERSION FILM COMPRISING THE SAME
EP3687989A4 (en)	2021-05-19	PYRIMIDINE COMPOUND PIPERAZINE SUBSTITUTE AND ITS USE
EP3494119A4 (en)	2020-03-25	COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
EP3303498A4 (en)	2019-01-23	PHOTO-CURABLE ADHESIVE COMPOSITION, PREPARATION THEREOF, AND USE THEREOF
EP3415502A4 (en)	2019-02-27	SUBSTITUTED HETEROARYL COMPOUND, COMPOSITION CONTAINING THE SAME, AND APPLICATION THEREOF
IL276753A (en)	2020-10-29	Afibrotic compounds, devices, and uses thereof
EP3328800A4 (en)	2019-01-09	POLYMERIC COMPOSITIONS INHIBITING THE TARKET, MIXTURES AND METHODS OF USE
HUE062893T2 (en)	2023-12-28	Stable semaglutide compositions and their applications
EP3681877A4 (en)	2021-02-24	COMPOUND DERIVED FROM PYRAZOLE AND ITS USE
DK3592430T3 (en)	2024-09-16	ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND USES THEREOF
EP3522282A4 (en)	2020-01-01	ELECTRODE, AND ACCUMULATOR COMPRISING SAME
IL253705B (en)	2020-09-30	Substituted triazoles, compositions comprising same and uses thereof

Legal Events

Date	Code	Title	Description
2019-03-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2020-04-17	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2020-04-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2020-05-20	17P	Request for examination filed	Effective date: 20200211
2020-05-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2020-05-20	AX	Request for extension of the european patent	Extension state: BA ME
2020-06-17	A4	Supplementary search report drawn up and despatched	Effective date: 20200520
2020-06-17	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/506 20060101ALI20200514BHEP Ipc: A61P 31/00 20060101ALI20200514BHEP Ipc: A61P 9/00 20060101ALI20200514BHEP Ipc: A61P 31/12 20060101ALI20200514BHEP Ipc: A61P 29/00 20060101ALI20200514BHEP Ipc: C07D 403/04 20060101AFI20200514BHEP Ipc: A61K 31/5377 20060101ALI20200514BHEP Ipc: A61P 37/02 20060101ALI20200514BHEP Ipc: A61P 3/00 20060101ALI20200514BHEP Ipc: A61P 35/00 20060101ALI20200514BHEP
2020-12-09	DAV	Request for validation of the european patent (deleted)
2020-12-09	DAX	Request for extension of the european patent (deleted)
2021-01-13	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: SHENZHEN TARGETRX, INC.
2021-04-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-05-05	17Q	First examination report despatched	Effective date: 20210331
2022-06-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602018044859 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07D0403140000 Ipc: C07D0403040000
2022-07-22	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2022-07-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2022-08-03	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/5377 20060101ALI20220624BHEP Ipc: A61K 31/506 20060101ALI20220624BHEP Ipc: A61P 37/06 20060101ALI20220624BHEP Ipc: A61P 35/02 20060101ALI20220624BHEP Ipc: A61P 35/00 20060101ALI20220624BHEP Ipc: A61P 31/12 20060101ALI20220624BHEP Ipc: A61P 31/00 20060101ALI20220624BHEP Ipc: A61P 29/00 20060101ALI20220624BHEP Ipc: A61P 9/00 20060101ALI20220624BHEP Ipc: A61P 3/00 20060101ALI20220624BHEP Ipc: C07D 403/04 20060101AFI20220624BHEP
2022-08-17	INTG	Intention to grant announced	Effective date: 20220722
2022-11-21	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2022-11-25	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2022-11-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2022-12-28	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-12-28	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2022-12-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2023-01-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602018044859 Country of ref document: DE
2023-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1540412 Country of ref document: AT Kind code of ref document: T Effective date: 20230115
2023-01-18	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2023-04-11	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2023-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230328 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2023-05-03	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20221228
2023-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1540412 Country of ref document: AT Kind code of ref document: T Effective date: 20221228
2023-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230329
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230530
2023-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230428 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2023-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230428 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2023-09-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602018044859 Country of ref document: DE
2023-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2023-11-03	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2023-11-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2023-12-06	26N	No opposition filed	Effective date: 20230929
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2024-03-12	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2024-03-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2024-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2024-04-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230821
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230821 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230831
2024-05-06	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20230831
2024-05-22	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2024-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2024-07-05	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230821
2024-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230821
2024-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230831
2024-11-08	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2024-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228
2025-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250610 Year of fee payment: 8
2025-07-25	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20180821
2025-08-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20180821
2025-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20250624 Year of fee payment: 8
2025-10-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20250703 Year of fee payment: 8
2025-12-12	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221228